Medical school

Treatment.com AI Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024

VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to provide a general corporate update. Treatment has been working diligently to continue its acceleration into the US market. A few key milestones the Company has accomplished are as follows:

Key Points: 
  • Treatment Provides Platform to Support Healthcare in Nairobi, Kenya
    VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”) is pleased to provide a general corporate update.
  • Dr. Kevin Peterson is the Founder and Chief Medical Officer of Treatment.com AI Inc.
  • Whilst utilizing AI, the GLM has been curated & evaluated by 150+ physicians globally to be correct, reliable and accurate.
  • Treatment’s platform provides clinical decision support to assist the healthcare workers in making an accurate diagnosis.

AOFAS Honors Two Female Orthopaedic Leaders

Retrieved on: 
Tuesday, February 27, 2024

“I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”

Key Points: 
  • “I am proud that AOFAS is making an effort to recognize women in foot and ankle orthopaedic surgery.”
    Over the past 15 years, Dr. Chou has conducted several research studies to examine breast cancer prevalence among female orthopaedic surgeons.
  • Dr. Chou’s research results confirmed higher breast cancer prevalence among female orthopaedic surgeons than the general population, and in a later study, she discovered higher prevalence among female orthopaedic surgeons compared to women in other surgical specialties.
  • Currently, she is leading a study to evaluate cancer risk associated with radiation exposure in male and female orthopaedic surgeons.
  • I applaud AOFAS for taking that initiative with these awards.”
    Funding for the AOFAS Women’s Leadership Initiative is provided by the Orthopaedic Foot & Ankle Foundation, supported by a grant from Treace Medical Concepts, Inc.

Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024

Retrieved on: 
Tuesday, February 27, 2024

MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.

Key Points: 
  • MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024) , taking place in Lisbon, Portugal March 5-9, 2024.
  • Maria Maccecchini, PhD, Founder, President, and CEO of Annovis, will join a forum discussion focused on new approaches for alpha-synuclein (αSyn), LRKK2, and GBA pathologies.
  • Aggregated αSyn is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
  • It is present in a number of other neurodegenerative diseases and is responsible for axonal impairment and synaptic degeneration.

Asha Therapeutics to Present at AD/PD™ 2024 International Conference and Announces Clinical Development Plan for Lead Programs Anticipated to Enter Clinical Trials this Year and Welcomes Two New SAB Members

Retrieved on: 
Friday, March 8, 2024

Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.

Key Points: 
  • Dr. Heckmann’s presentation is titled ASHA-091: Novel Pharmacological Targeting of Mitochondrial Dysfunction to Ameliorate Parkinson’s & Alzheimer’s Disease Pathology.
  • ASHA-091 restores normal mitochondrial function and has demonstrated disease modifying efficacy as a functional cure in preclinical disease models.
  • In preparation for clinical transition, Asha has appointed Dr. Michael Gold and Dr. Allan Levey to their Scientific Advisory Board.
  • Their expertise comes at a pivotal moment for Asha as we transition our first-in-class lead programs designed using our PRISM™ technology to clinical trials.

REVEAL GENOMICS® HER2DX® Genomic Test to Undergo First Prospective Trial as Part of the DEFINITIVE Project, Funded by the European Commission

Retrieved on: 
Wednesday, February 28, 2024

The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe.

Key Points: 
  • The study seeks to secure the prospective validation for endorsement by clinical guidelines and ensure recognition and reimbursement across Europe.
  • As a collaborating partner in this study, REVEAL GENOMICS® is committed to generating robust evidence designed to influence and evolve standard clinical practices.
  • We are immensely grateful to all our partners and the multidisciplinary team participating in this trial.
  • The DEFINITIVE trial seeks to assess the clinical efficacy of HER2DX® by comparing the outcomes of patients who undergo the genomic test with those who do not.

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

Retrieved on: 
Monday, February 26, 2024

These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.

Key Points: 
  • These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.
  • This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.
  • Traditional AD diagnosis has relied on combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD.
  • “In our pursuit to build the global testing infrastructure for Alzheimer’s disease, Quanterix is pleased to work with several health systems whose combined networks treat millions of patients,” said Masoud Toloue, CEO of Quanterix.

Haymarket Medical Education and myCME, in Partnership With Sleep-Wake Advisor, Announce Launch of the Sleep-Wake Advisor Institute

Retrieved on: 
Wednesday, February 21, 2024

“Today is an exciting day in the field of Sleep-Wake medicine,” said Jacqui Brooks, MBBCh, MRCPsych, Vice President, Medical Strategy at Haymarket Medical Education.

Key Points: 
  • “Today is an exciting day in the field of Sleep-Wake medicine,” said Jacqui Brooks, MBBCh, MRCPsych, Vice President, Medical Strategy at Haymarket Medical Education.
  • “The launch of the Sleep-Wake Advisor Institute demonstrates Haymarket’s commitment to sleep medicine and its impact across medicine, and will provide a long-needed, one-of-a-kind resource for sleep-wake clinicians.
  • This year will also see the launch of Sleep-Wake Advisor in Spring 2024 and our Sleep-Wake Advisor Summit in June.”
    “Sleep-Wake Advisor Institute is more than an educational platform.
  • To learn more and become part of the Sleep-Wake Advisor Institute community, CLICK HERE .

California University of Science and Medicine Successfully Progresses With Accreditation from LCME

Retrieved on: 
Wednesday, February 21, 2024

California University of Science and Medicine (CUSM) School of Medicine today announced that the Liaison Committee on Medical Education (LCME) awarded Provisional Accreditation to the university's Doctor of Medicine program.

Key Points: 
  • California University of Science and Medicine (CUSM) School of Medicine today announced that the Liaison Committee on Medical Education (LCME) awarded Provisional Accreditation to the university's Doctor of Medicine program.
  • LCME Accreditation is a multi-step process ensuring rigorous and complete review of medical schools in the United States.
  • Provisional Accreditation is the last step before Full Accreditation status can be achieved.
  • Additionally, a cohort of 60 students are selected each year for the 10-month Master of Biomedical Sciences degree.

VPL onboards seven new health orgs, reaffirms commitment to customer satisfaction

Retrieved on: 
Wednesday, March 6, 2024

COLUMBUS, Ohio, March 6, 2024 /PRNewswire-PRWeb/ -- Clinical supply chain management provider VPL onboarded over seven new health organizations in 2023, including Allina Health, Anderson Hospital, Medical University of South Carolina (MUSC), Riverside Medical Center, Rocky Mountain Vital Care, Sarasota Specialty Rx and Innoterix Labs.

Key Points: 
  • Clinical supply chain management provider VPL onboarded over seven new health organizations in 2023, including Allina Health, Anderson Hospital, Medical University of South Carolina (MUSC), Riverside Medical Center, Rocky Mountain Vital Care, Sarasota Specialty Rx and Innoterix Labs.
  • COLUMBUS, Ohio, March 6, 2024 /PRNewswire-PRWeb/ -- Clinical supply chain management provider VPL onboarded over seven new health organizations in 2023, including Allina Health, Anderson Hospital, Medical University of South Carolina (MUSC), Riverside Medical Center, Rocky Mountain Vital Care, Sarasota Specialty Rx and Innoterix Labs.
  • The healthcare landscape is rapidly evolving, and health systems are increasingly recognizing the importance of strategic conversations and scalable solutions in clinical supply chain management.
  • To stay competitive in this evolving landscape, VPL announced their commitment to broadening the scope of value they provide.

BRAINBox Solutions to Present Updated Data at Three Leading Conferences from HeadSMART II and NIH-funded Geriatrics Clinical Trials of BRAINBox TBI Concussion Test

Retrieved on: 
Monday, March 4, 2024

RICHMOND, Va., March 4, 2024 /PRNewswire/ -- BRAINBox Solutions today announced current and upcoming presentations of clinical trends and data at three leading, upcoming medical conferences from the HeadSMART II pivotal trial in adult patients and the National Institutes of Health (NIH) funded clinical trial in geriatric patients of its BRAINBox TBI™ concussion diagnostic and prognostic test.  Concussion is also known as ATE (Acute Traumatic Encephalopathy) or mTBI (mild traumatic brain injury).

Key Points: 
  • The presentation title is, "Biomarker Profiles Distinguish Geriatric Acute TBI from Dementias:  Results from the HeadSMARTII Geriatric Feasibility Study.
  • "  The poster title is: "Biomarker Profiles Distinguish Geriatric TBI from Dementias:  Results From the HeadSMART Geriatric Feasibility Study."
  • "These presentations highlight the breadth of clinical data being assembled to evaluate the diagnostic and prognostic potential of the BRAINBox TBI test across a spectrum of age groups.
  • "These two trials have made substantial progress, as enrollment in both is expanding and, in the case of HeadSMART II, almost completed," said Donna Edmonds, BRAINBox Solutions' CEO.